Identification of anti-EGFR and anti-ErbB3 dual variable domains immunoglobulin (DVD-Ig) proteins with unique activities

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Gu, Jinming ^a   Yang, Jinsong ^a,b   Chang, Qing ^a   Liu, Zhihong ^a   Ghayur, Tariq ^a   Gu, Jijie ^a  

^a ABBVIE INC   (United States)

^b Shire Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA HEREGULIN; DUAL VARIABLE DOMAINS IMMUNOGLOBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN; NEU DIFFERENTIATION FACTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; IMMUNOGLOBULIN VARIABLE REGION; LIGAND; PROTEIN BINDING; RECOMBINANT PROTEIN;

A431 CELL LINE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL LINE; CELL PROLIFERATION; DOWN REGULATION; DRUG MECHANISM; FADU CELL LINE; IMMUNOBLOTTING; INTERNALIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PURIFICATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LIGANDS; NEUREGULIN-1; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84930629876     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124135     Document Type: Article

References (18)

1. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83-6. PMID: 9247128
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54. PMID: 15864276
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019 PMID: 19339720
4. Fukuda K, Saikawa Y, Takahashi M, Takahashi T, Wada N, Kawakubo H et al. Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells. Int J Oncol; 40: 975-82. doi: 10.3892/ijo.2011.1279 PMID: 22139134
5. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol; 28: 911-7. doi: 10.1200/JCO.2009.21.9618 PMID: 20100966
6. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res; 70: 2485-94. doi: 10.1158/0008-5472. CAN-09-3145 PMID: 20215504
7. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2: ra31. doi: 10.1126/scisignal.2000352 PMID: 19567914
8. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell; 17: 298-310. doi: 10.1016/j.ccr.2009.12.047 PMID: 20227043
9. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12: 4103-11. PMID: 16818711
10. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell; 20: 472-86. doi: 10.1016/j.ccr.2011.09.003 PMID: 22014573
11. Wu C, Ying H, Bose S, Miller R, Medina L, Santora L et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1: 339-47. PMID: 20068402
12. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269: 14661-5. PMID: 7514177
13. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene; 22:761-68. PMID: 12569369
14. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. The Cancer Journal From Scientific American; 3:21-30. PMID: 9072304
15. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathology Oncology Research; 7:171-7. PMID: 11692142
16. Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M et al. Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig) Proteins with Unique Activities. PLOS One; 9:e97292. doi: 10.1371/journal.pone.0097292 PMID: 24824849
17. DiGiammarino E, Ghayur T, Liu J. Design and generation of DVD-Ig molecules for dual-specific targeting. Methods Mol Biol; 899: 145-56. doi: 10.1007/978-1-61779-921-1-9 PMID: 22735951
18. Jakob CG, Edalji R, Judge RA, DiGiammarino E, Li Y, Gu J et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule. MAbs; 5.